DEK Expression is Controlled by E2F and Deregulated in Diverse Tumor Type

 Abstract

Deregulation of the retinoblastoma (pRB) tumor suppressor pathway associated with aberrant activity of E2F transcription factors is frequently observed in human cancer. Microarray based analyses have revealed a large number of potential downstream mediators of the tumor suppressing activity of pRB, including DEK, a fusion partner of CAN found in a subset of acute myeloid leukaemia (AML) patients carrying a (6; 9) translocation.
Here we report that the expression of DEK is under direct control of E2F transcription factors. Chromatin immunoprecipitation assays show that the DEK promoter is bound by endogenous E2F in vivo. The DEK promoter is transactivated by E2F and mutation of E2F binding sites eliminates this effect. Expression levels of DEK in human tumors have been investigated by tissue micro array analysis. We find that DEK is overexpressed in many solid tumors such as colon cancer, larynx cancer, bladder cancer, and melanoma.

Full Text Options
Article
Metrics
 Share
 Full Text
 Info
Pages
1202 - 1207
doi
10.4161/cc.5.11.2801
Type
Brief Report
 Metrics
 Cite This Article
 Permissions
 Permissions
 Reprints
DEK Expression is Controlled by E2F and Deregulated in Diverse Tumor Type